New drug combo for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cervical cancer that is squamous cell, adenosquamous, or HPV-related adenocarcinoma.
- Your cancer has returned or spread, and standard treatments have not worked or caused too many side effects—but you've had no more than 3 prior treatments for this stage, and only one of those was an immunotherapy (like a PD-1 blocker).
- You must have at least one measurable tumor (shown on a scan) and be 18 or older.
- You should be well enough to do light work or daily activities (ECOG score 0 or 1), and have good liver, kidney, and blood cell function.
- You must not have significant bleeding risks, uncontrolled blood pressure, or other major health problems like active autoimmune disease or unstable brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This study tests a new combination of immunotherapy drugs for cervical cancer that has spread or returned. It aims to see if the treatment can shrink tumors and improve outcomes for people whose cancer is not curable with standard treatments.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a new immunotherapy drug (QL1706) for cervical cancer that has stopped responding to earlier PD-1 therapies. The goal is to see if this drug can help shrink tumors or slow down the cancer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.